Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease

W. Jongbloed, K.D. van Dijk, S.D. Mulder, W.D.J. van de Berg, M.A. Blankenstein, W.M. van der Flier, R. Veerhuis

    Research output: Contribution to JournalArticleAcademicpeer-review

    Abstract

    Background: Increased clusterin levels have been reported in brain, cerebrospinal fluid (CSF), and plasma of Alzheimer's disease (AD) patients. Because changes are also observed in mild cognitive impairment (MCI), a possible relationship between clusterin levels and early neurodegenerative changes in AD was suggested. Objectives: To determine whether clusterin concentrations could 1) serve as a diagnostic marker for AD, 2) predict disease progression in MCI, and 3) correlate with AD-biomarkers. Methods: Clusterin levels in CSF and plasma, as well as AD biomarker levels of Aβ
    Original languageEnglish
    Pages (from-to)1103-1110
    JournalJournal of Alzheimer's Disease
    Volume46
    Issue number4
    DOIs
    Publication statusPublished - 2015

    Fingerprint Dive into the research topics of 'Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease'. Together they form a unique fingerprint.

  • Cite this

    Jongbloed, W., van Dijk, K. D., Mulder, S. D., van de Berg, W. D. J., Blankenstein, M. A., van der Flier, W. M., & Veerhuis, R. (2015). Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. Journal of Alzheimer's Disease, 46(4), 1103-1110. https://doi.org/10.3233/JAD-150036